Gética 2020

32 VI FORO DE Inmunología Traslacional e INMUNOTERAPIA DEL CÁNCER 11. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepa- tocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2020;38(3): 193-202. 12. Diaz LA, Marabelle A, Delord JP, et al. Pembrolizum- ab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol 2017;35:3071. 13. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-defi- cient or microsatellite instability high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182-91.